GlobeNewswire Inc.May 27, 7:00 AM ET▲ Positive
The company reported favorable Phase 1 results demonstrating low drug-drug interaction potential for its lead HCV candidate, supporting its best-in-class profile. Additionally, promising preclinical data for AT-587 in HEV treatment addresses an unmet medical need in immunocompromised patients. Phase 3 trials for HCV remain on track with topline results expected mid-2026, indicating progress toward potential commercialization.